Jefferies Starts AC Immune SA (ACIU) at Buy
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Leerink Partners Starts AC Immune SA (ACIU) at Outperform
October 18, 2016 6:44 AM EDTLeerink Partners initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $22.00.
Analyst Paul Matteis commented, "AC Immune is a biotechnology company that is focused on developing novel medicines for neurodegenerative disorders. ACIU's lead asset crenezumab... More
Credit Suisse Starts AC Immune SA (ACIU) at Outperform
October 18, 2016 6:29 AM EDTCredit Suisse initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $18.00.
Analyst Alethia Young commented, "AC Immune is focused on neurodegenerative diseases, primarily Alzheimers Disease (AD). Their lead asset, crenezumab, is in Phase 3 in... More